InvestSMART

Anatara Lifesciences Ltd (ASX:ANR)

ALERT: Price-sensitive ASX Announcement for ANR
Current share price for ANR : $0.009 -0.001 (-10%)+
Announcement
Release
31 Jul 2026 4:46PM
Price at Release
$0.010
Full Release
download
Summary
Anatara Lifesciences Ltd (ASX: ANR) has released its Appendix 4C and Quarterly Activities Report for Q4 FY26, highlighting key developments and financial updates. The company is advancing its Anti-Obesity Project, where pre-clinical studies demonstrated the efficacy of a compound known as AOC in managing weight reduction. The company is considering an open label trial and assessing the commercial potential of AOC. Financially, the company ended the quarter with $0.471 million in cash, and net cash outflows from operating activities were $0.286 million. Anatara is also involved in ongoing corporate activities and exploring additional opportunities and strategic directions within the healthcare sector.
Key Points
  • Completion of Anti-Obesity Project pre-clinical studies showing AOC's efficacy.
  • Possible open label trial for compound AOC under consideration.
  • Cash balance at quarter end: $0.471 million.
  • Net cash outflow from operating activities: $0.286 million.
  • Continuing business development and M&A discussions.
  • Exploring additional opportunities in the healthcare sector.
  • Lodged R&D tax incentive claim with AusIndustry.
  • Focus on projects addressing unmet medical needs.
  • GaRP project IP has commercial interest.
  • Ongoing corporate activities to determine cash needs and funding availability.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.